logo
Plus   Neg
Share
Email

Hikma Pharma Completes FDA Response For Generic Advair Diskus

Hikma Pharmaceuticals Plc. (HIK.L, HKMPY.PK) said that it has submitted to the US Food and Drug Administration its response to deficiencies in its abbreviated new drug application for a generic version of GlaxoSmithKline's Advair Diskus.

Hikma initiated a clinical endpoint study in 2018, following receipt of a complete response letter from the FDA.

Siggi Olafsson, Chief Executive Officer of Hikma, said "We are confident in our ability to bring a generic version of Advair to the US market, which would enable us to improve patient access to this important medicine."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients. Ferring Pharmaceuticals US is recalling various nasal sprays citing superpotency or amounts of desmopressin higher than specified, the U.S. Food and Drug Administration announced in a statement. The recall involves all lots on the market of DDAVP Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE Nasal Spray 1.5 mg/mL. U.S. President Donald Trump has issued executive orders to ban Chinese mobile application TikTok as well as WeChat, citing a threat to national security and its economy. China's ByteDance Ltd. owns TikTok, a video-sharing mobile app, while Tencent Holdings Ltd. owns WeChat, a messaging, social media, and electronic payment app.
Follow RTT